Form4insider filings, from the source

SEC Form 4 · accession 0000899243-16-033506

Aimmune Therapeutics, Inc. · AIMT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Stephen George Dilly
Officer — See Remarks · Director
Period of report
Nov 10, 2016
Accepted (ET)
Nov 15, 2016 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Stock, $0.0001 par valueF2,F3Jul 25, 2016G14,447$0.00A779,755D
Common Stock, $0.0001 par valueF4Jul 25, 2016G14,447$0.00D51,403IBy GRAT 1
Common Stock, $0.0001 par valueJul 25, 2016G14,447$0.00A14,447IBy Wife
Common Stock, $0.0001 par valueF6Jul 25, 2016G14,447$0.00D51,403IBy Wife's GRAT 1
Common Stock, $0.0001 par valueF2Aug 24, 2016G14,447$0.00D765,308D
Common Stock, $0.0001 par valueF8Aug 24, 2016G14,447$0.00A14,447IBy GRAT 2
Common Stock, $0.0001 par valueAug 24, 2016G14,447$0.00D0IBy Wife
Common Stock, $0.0001 par valueF10Aug 24, 2016G14,447$0.00A14,447IBy Wife's GRAT 2
Common Stock, $0.0001 par valueF2Nov 10, 2016S1,304$25.00D764,004D
Common Stock, $0.0001 par valueF12,F2Nov 11, 2016S23,696$25.0249D740,308D
Common Stock, $0.0001 par valueF2Nov 11, 2016S25,000$25.00D715,308D

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

Remarks

President and Chief Executive Officer